Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians

被引:14
作者
Sullivan, Emma [1 ]
Kershaw, Jim [1 ]
Blackburn, Stuart [1 ]
Choi, Jeannie [2 ]
Curtis, Jeffrey R. [3 ]
Boklage, Susan [4 ]
机构
[1] Adelphi Real World, Macclesfield, Cheshire, England
[2] Sanofi, Bridgewater, NJ USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
关键词
Biologic disease-modifying antirheumatic drugs; Cycling; Rheumatoid arthritis; Switching; Tumor necrosis factor inhibitors; ANTITUMOR NECROSIS FACTOR; CONCOMITANT METHOTREXATE; TREATMENT PERSISTENCE; MONOCLONAL-ANTIBODY; THERAPY; OUTCOMES; MONOTHERAPY; ADALIMUMAB; MANAGEMENT; MECHANISM;
D O I
10.1007/s40744-020-00203-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Some patients with rheumatoid arthritis (RA) using tumor necrosis factor inhibitors (TNFi) experience inefficacy or lack of tolerability and hence switch to another TNFi (cycling) or to a therapy with another mode of action (switching). This study examined patient characteristics, prescribing patterns and treatment practice for RA in the United States. Methods Data were from the Adelphi Disease Specific Programme (Q2-Q3 2016). Rheumatologists completed a survey and patient record forms for adult patients with RA who had received >= 1 targeted therapy. Patients were grouped by class of first-used targeted therapy, and monotherapy vs. combination therapy. TNFi patients who received >= 1 targeted therapy were classified as cyclers or switchers. Univariate analyses compared patient characteristics and physician factors across the analysis groups. Results Overall, 631 patients received >= 1 targeted therapy; 535 were prescribed a TNFi as first targeted therapy, 53 a nonTNFi biologic disease-modifying antirheumatic drug (bDMARD), and 43 tofacitinib. Of 577 patients with known conventional synthetic (cs) DMARD status, 18.7% were prescribed monotherapy and 81.3% combination therapy. Combination therapy patients received significantly more concomitant medications prior to initiation of first targeted therapy than monotherapy patients (P < 0.05). The top reason for physicians to prescribe first use targeted therapy was strong overall efficacy (79.9%). Of 163 patients who progressed to second targeted therapy, 60.7% were cyclers. A lower proportion of cyclers persisted on their first use targeted therapy versus switchers (P = 0.03). The main reason physicians gave for switching patients at this stage was worsening condition (46.6%). Conclusions Most patients were prescribed a TNFi as their first targeted therapy; over half then cycled to another TNFi. This suggests other factors may influence second use targeted treatment choice and highlights the need for greater understanding of outcomes associated with subsequent treatment choices and potential benefits of switching.
引用
收藏
页码:383 / 400
页数:18
相关论文
共 22 条
[1]  
Anderson P, 2008, CURR MED RES OPIN, V24, P3063, DOI [10.1185/03007990802457040, 10.1185/03007990802457040 ]
[2]   Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings [J].
Bonafede, Machaon ;
Fox, Kathleen M. ;
Watson, Crystal ;
Princic, Nicole ;
Gandra, Shravanthi R. .
ADVANCES IN THERAPY, 2012, 29 (08) :664-674
[3]   Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis [J].
Cannon, Grant W. ;
DuVall, Scott L. ;
Haroldsen, Candace L. ;
Caplan, Liron ;
Curtis, Jeffrey R. ;
Michaud, Kaleb ;
Mikuls, Ted R. ;
Reimold, Andreas ;
Collier, David H. ;
Harrison, David J. ;
Joseph, George J. ;
Sauer, Brian C. .
JOURNAL OF RHEUMATOLOGY, 2014, 41 (10) :1935-1943
[4]   Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA [J].
Chastek, Benjamin ;
Chen, Chieh-I ;
Proudfoot, Clare ;
Shinde, Shraddha ;
Kuznik, Andreas ;
Wei, Wenhui .
ADVANCES IN THERAPY, 2017, 34 (11) :2422-2435
[5]   Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis [J].
Chastek, Benjamin ;
Becker, Laura K. ;
Chen, Chieh-I ;
Mahajan, Puneet ;
Curtis, Jeffrey R. .
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (05) :464-473
[6]   Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis [J].
Choy, Ernest ;
Aletaha, Daniel ;
Behrens, Frank ;
Finckh, Axel ;
Gomez-Reino, Juan ;
Gottenberg, Jacques-Eric ;
Schuch, Florian ;
Rubbert-Roth, Andrea .
RHEUMATOLOGY, 2017, 56 (05) :689-697
[7]   The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study [J].
Cross, Marita ;
Smith, Emma ;
Hoy, Damian ;
Carmona, Loreto ;
Wolfe, Frederick ;
Vos, Theo ;
Williams, Benjamin ;
Gabriel, Sherine ;
Lassere, Marissa ;
Johns, Nicole ;
Buchbinder, Rachelle ;
Woolf, Anthony ;
March, Lyn .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (07) :1316-1322
[8]   Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis [J].
Emery, Paul ;
Sebba, Anthony ;
Huizinga, Tom W. J. .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (12) :1897-1904
[9]   Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs [J].
Engel-Nitz N.M. ;
Ogale S. ;
Kulakodlu M. .
Rheumatology and Therapy, 2015, 2 (2) :127-139
[10]   The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives [J].
Favalli, Ennio Giulio ;
Raimondo, Maria Gabriella ;
Becciolini, Andrea ;
Crotti, Chiara ;
Biggioggero, Martina ;
Caporali, Roberto .
AUTOIMMUNITY REVIEWS, 2017, 16 (12) :1185-1195